Your browser is no longer supported. Please, upgrade your browser.
Settings
SGEN Seattle Genetics, Inc. daily Stock Chart
SGEN [NASD]
Seattle Genetics, Inc.
Index- P/E- EPS (ttm)-0.87 Insider Own1.10% Shs Outstand142.62M Perf Week-0.32%
Market Cap8.45B Forward P/E- EPS next Y-1.16 Insider Trans-16.68% Shs Float142.27M Perf Month2.40%
Income-121.50M PEG- EPS next Q-0.44 Inst Own- Short Float8.96% Perf Quarter10.48%
Sales457.90M P/S18.46 EPS this Y-6.70% Inst Trans2.16% Short Ratio13.07 Perf Half Y-6.32%
Book/sh4.60 P/B12.88 EPS next Y-26.10% ROA-15.00% Target Price64.57 Perf Year-11.46%
Cash/sh3.16 P/C18.76 EPS next 5Y- ROE-19.70% 52W Range45.31 - 71.32 Perf YTD12.30%
Dividend- P/FCF- EPS past 5Y5.80% ROI-22.50% 52W High-16.90% Beta2.39
Dividend %- Quick Ratio3.70 Sales past 5Y34.60% Gross Margin89.10% 52W Low30.79% ATR2.01
Employees890 Current Ratio4.10 Sales Q/Q27.30% Oper. Margin-45.10% RSI (14)51.66 Volatility3.99% 3.25%
OptionableYes Debt/Eq0.00 EPS Q/Q249.90% Profit Margin-26.50% Rel Volume0.71 Prev Close57.27
ShortableYes LT Debt/Eq0.00 EarningsJan 25 AMC Payout- Avg Volume975.11K Price59.26
Recom2.30 SMA201.52% SMA50-0.53% SMA2000.34% Volume687,855 Change3.47%
Nov-13-17Reiterated RBC Capital Mkts Outperform $68 → $69
Oct-27-17Upgrade BofA/Merrill Underperform → Neutral
Oct-24-17Resumed Guggenheim Buy $72
Oct-20-17Upgrade Barclays Equal Weight → Overweight $60 → $70
Oct-06-17Resumed Goldman Neutral
Sep-15-17Initiated RBC Capital Mkts Outperform $58
Mar-16-17Initiated Oppenheimer Perform
Feb-10-17Downgrade BofA/Merrill Neutral → Underperform
Dec-12-16Downgrade Credit Suisse Outperform → Neutral
Dec-06-16Reiterated RBC Capital Mkts Outperform $62 → $72
Oct-10-16Reiterated RBC Capital Mkts Outperform $55 → $62
Sep-15-16Upgrade Goldman Sell → Neutral
Sep-07-16Initiated Morgan Stanley Overweight
Jul-27-16Reiterated SunTrust Neutral $34 → $38
Jul-27-16Reiterated RBC Capital Mkts Outperform $125 → $130
Jul-27-16Reiterated Barclays Overweight $48 → $53
Jul-27-16Downgrade Cantor Fitzgerald Buy → Hold
Mar-03-16Initiated Sun Trust Rbsn Humphrey Neutral $34
Feb-10-16Upgrade Cantor Fitzgerald Hold → Buy
Feb-10-16Reiterated Piper Jaffray Neutral $44 → $33
Dec-10-17 06:33PM  Takeda and Seattle Genetics to Present Positive Data from Phase 3 ECHELON-1 Clinical Trial Evaluating ADCETRIS® (brentuximab vedotin) in Frontline Advanced Hodgkin Lymphoma Business Wire
09:00AM  Seattle Genetics Highlights Five-Year Survival Results from Phase 1 Trial of ADCETRIS® (Brentuximab Vedotin) in Frontline Mature T-Cell Lymphoma at ASH Annual Meeting Business Wire
Dec-09-17 09:00AM  Seattle Genetics Highlights Updated Analyses from Phase 3 ALCANZA Clinical Trial of ADCETRIS® (Brentuximab Vedotin) in CD30-Expressing Cutaneous T-Cell Lymphoma at ASH Annual Meeting Business Wire
Dec-08-17 08:07AM  See what the IHS Markit Score report has to say about Seattle Genetics Inc. Markit
07:45AM  Immunomedics' Data Is Good News for Seattle Genetics, Too Motley Fool
Dec-07-17 08:00AM  Seattle Genetics Presents Updated Phase 1 Data for Ladiratuzumab Vedotin (SGN-LIV1A) in Patients with Triple Negative Breast Cancer at 2017 San Antonio Breast Cancer Symposium Business Wire
Dec-06-17 03:58PM  Why Immunomedics, Inc. Is Soaring Today Motley Fool
Dec-04-17 09:03AM  What Analysts Recommend for United Therapeutics in November 2017 Market Realist
08:00AM  Seattle Genetics to Webcast Investor and Analyst Event at American Society of Hematology Annual Meeting Business Wire
07:30AM  Market-Moving News Is on Tap for Seattle Genetics Motley Fool
Dec-01-17 08:10AM  Todays Research Reports on Stocks to Watch: Seattle Genetics and Alnylam Pharmaceuticals ACCESSWIRE
Nov-29-17 03:56AM  Why Is Seattle Genetics (SGEN) Down 4.1% Since the Last Earnings Report? Zacks
Nov-28-17 07:52AM  Seattle Genetics, Inc. breached its 50 day moving average in a Bearish Manner : SGEN-US : November 28, 2017 Capital Cube
Nov-15-17 01:17PM  Seattle Genetics, Inc. Value Analysis (NASDAQ:SGEN) : November 15, 2017 Capital Cube
Nov-14-17 10:26AM  Seattle Genetics, Inc. breached its 50 day moving average in a Bearish Manner : SGEN-US : November 14, 2017 Capital Cube
Nov-13-17 09:41AM  Seattle Genetics' Adcetris Gets FDA Nod for Label Expansion Zacks
Nov-10-17 08:30AM  Report: Exploring Fundamental Drivers Behind Tronox, Ameren, GrubHub, Patterson Companies, AVEO Pharmaceuticals, and Seattle Genetics New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
Nov-09-17 12:40PM  Seattle Genetics Announces FDA Approval of ADCETRIS® (Brentuximab Vedotin) for Primary Cutaneous Anaplastic Large Cell Lymphoma (pcALCL) and CD30-Expressing Mycosis Fungoides (MF) Business Wire
Nov-08-17 08:00AM  Seattle Genetics and Astellas Initiate Phase 1b Trial of Enfortumab Vedotin in Combination with Immune Checkpoint Inhibitor Therapies in Locally Advanced or Metastatic Urothelial Cancer Business Wire
08:00AM  Astellas and Seattle Genetics Initiate Phase 1b Trial of Enfortumab Vedotin in Combination with Immune Checkpoint Inhibitor Therapies in Locally Advanced or Metastatic Urothelial Cancer PR Newswire
Nov-02-17 08:00AM  Seattle Genetics Submits Supplemental Biologics License Application to FDA for ADCETRIS® (Brentuximab Vedotin) in Frontline Advanced Hodgkin Lymphoma Business Wire
07:40AM  Earnings Review and Free Research Report: Biogens Adjusted EPS Surged 25.1% ACCESSWIRE
Nov-01-17 02:17PM  Seattle Genetics, Inc.: Double-Digit Revenue Growth, but the Best Is Yet to Come Motley Fool
09:00AM  Seattle Genetics to Present Data from Broad ADCETRIS® (Brentuximab Vedotin) Development Program at ASH 2017 Business Wire
07:10AM  Featured Company News - FDA Granted Orphan Drug Designation to Merrimack's MM-121 for Treatment of Heregulin Positive Non-Small Cell Lung Cancer ACCESSWIRE
Oct-30-17 03:00AM  IBD Rating Upgrades: Seattle Genetics Flashes Improved Price Strength Investor's Business Daily
01:45AM  Edited Transcript of SGEN earnings conference call or presentation 26-Oct-17 8:30pm GMT Thomson Reuters StreetEvents
Oct-27-17 11:42AM  Seattle Genetics (SGEN) Loss Narrows in Q3, Revenues Beat Zacks
09:35AM  Versartis Drops on Q3 Numbers, Hires Adviser -- Biotech Movers TheStreet.com
Oct-26-17 05:29PM  Seattle Genetics tops Street 3Q forecasts Associated Press
04:02PM  Seattle Genetics Reports Third Quarter 2017 Financial Results Business Wire
09:40AM  Seattle Genetics, Inc. to Host Earnings Call ACCESSWIRE
Oct-25-17 01:04PM  [$$] Seattle Genetics May See 'Significant Upside' Barrons.com
08:58AM  Should You Sell Seattle Genetics (SGEN) Before Earnings? Zacks
Oct-19-17 08:06AM  See what the IHS Markit Score report has to say about Seattle Genetics Inc. Markit
Oct-13-17 07:13PM  Cramers Exec Cut: CEO reveals his companys plans to dis... CNBC Videos
11:18AM  Cancer Space Update: Lung & Breast Cancer Studies in Focus Zacks
Oct-12-17 10:18AM  Seattle Genetics Inks Clinical Collaborations for Cancer Drug Zacks
08:20AM  Today's Research Reports on Stocks to Watch: Akari Therapeutics and Seattle Genetics ACCESSWIRE
Oct-11-17 07:10PM  Cramer Remix: Its not about sex appeal, its about timin... CNBC Videos +6.51%
07:02PM  Seattle Genetics CEO talks new cancer treatment pipeline,... CNBC Videos
06:59PM  Cramer Remix: Its not about sex appeal, its about timing CNBC
05:03PM  Why Snap, Seattle Genetics, and Pretium Resources Jumped Today Motley Fool
04:38PM  This Drugmaker Hit A 4-Month High On Collaboration With Dow's Merck Investor's Business Daily
10:29AM  Seattle Genetics Begins Phase II Study of Cancer Candidate Zacks
08:00AM  Seattle Genetics Announces Additional Clinical Collaborations to Evaluate SGN-LIV1A in Triple Negative Breast Cancer Business Wire
Oct-10-17 08:05AM  See what the IHS Markit Score report has to say about Seattle Genetics Inc. Markit
08:00AM  Seattle Genetics and Astellas Initiate Pivotal Trial of Enfortumab Vedotin for Patients with Locally Advanced or Metastatic Urothelial Cancer Business Wire
08:00AM  Astellas and Seattle Genetics Initiate Pivotal Trial of Enfortumab Vedotin for Patients with Locally Advanced or Metastatic Urothelial Cancer PR Newswire
06:44AM  Genmab and Seattle Genetics to Initiate New Study of Novel Antibody-Drug Conjugate Tisotumab Vedotin in Cervical Cancer Business Wire
Oct-09-17 10:13AM  Cancer Space Last Week Update: Pipeline Expansion in Focus Zacks
Oct-06-17 08:05AM  See what the IHS Markit Score report has to say about Seattle Genetics Inc. Markit
Oct-05-17 08:05AM  See what the IHS Markit Score report has to say about Seattle Genetics Inc. Markit
08:00AM  Seattle Genetics to Host Conference Call and Webcast Discussion of Third Quarter Financial Results on October 26, 2017 Business Wire
Oct-04-17 07:03PM  Cramer's lightning round: Why my charitable trust sold it... CNBC Videos
Oct-03-17 09:40AM  Seattle Genetics' Adcetris Gets Breakthrough Therapy Status Zacks
08:57AM  Seattle Genetics (SGEN) in Focus: Stock Moves 7.9% Higher Zacks
08:00AM  Seattle Genetics and Takeda Announce Publication in Blood of Final Long-Term Survival Data from ADCETRIS® (Brentuximab Vedotin) Pivotal Phase 2 Clinical Trial in Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma Business Wire
06:00AM  Biotech's Breakout To Start In The Fourth Quarter Investopedia
Oct-02-17 03:03PM  Green Monday for Capital Markets Around the Globe GuruFocus.com +7.92%
06:45AM  Seattle Genetics Receives FDA Breakthrough Therapy Designation for ADCETRIS® (Brentuximab Vedotin) in Frontline Advanced Hodgkin Lymphoma Business Wire
Sep-27-17 08:06AM  See what the IHS Markit Score report has to say about Seattle Genetics Inc. Markit
Sep-25-17 10:45AM  ETFs with exposure to Seattle Genetics, Inc. : September 25, 2017 Capital Cube
08:35AM  Bristol-Myers (BMY) Opdivo Gets Approval for Liver Cancer Zacks
Sep-17-17 05:43PM  Is Seattle Genetics Inc (SGEN) Undervalued? Simply Wall St.
Sep-14-17 08:06AM  See what the IHS Markit Score report has to say about Seattle Genetics Inc. Markit
Sep-13-17 08:28PM  ETFs with exposure to Seattle Genetics, Inc. : September 14, 2017 Capital Cube
Sep-11-17 02:09PM  Seattle Genetics, Inc. :SGEN-US: Earnings Analysis: Q2, 2017 By the Numbers : September 11, 2017 Capital Cube
Sep-08-17 10:25AM  See what the IHS Markit Score report has to say about Seattle Genetics Inc. Markit
10:00AM  Seattle Genetics Highlights Promising Data with Tisotumab Vedotin in Cervical Cancer at ESMO 2017 Congress Business Wire
Sep-06-17 08:00AM  Seattle Genetics to Present at Morgan Stanley Global Healthcare Conference Business Wire
Sep-05-17 08:05AM  See what the IHS Markit Score report has to say about Seattle Genetics Inc. Markit
Sep-01-17 10:09AM  Seattle Genetics, Inc. breached its 50 day moving average in a Bullish Manner : SGEN-US : September 1, 2017 Capital Cube
08:10AM  Today's Research Reports on Stocks to Watch: Seattle Genetics and Novartis ACCESSWIRE
Aug-31-17 08:11AM  See what the IHS Markit Score report has to say about Seattle Genetics Inc. Markit +5.52%
Aug-30-17 08:06AM  See what the IHS Markit Score report has to say about Seattle Genetics Inc. Markit
Aug-29-17 07:05AM  Genmab and Seattle Genetics to Co-develop Tisotumab Vedotin for Solid Tumors Business Wire
Aug-17-17 06:33PM  Seattle Genetics' Adcetris Granted Priority Review by FDA Zacks
Aug-16-17 08:06AM  See what the IHS Markit Score report has to say about Seattle Genetics Inc. Markit
08:00AM  FDA Accepts Supplemental Biologics License Application and Grants Priority Review for ADCETRIS® (Brentuximab Vedotin) in Cutaneous T-Cell Lymphoma Business Wire
Aug-15-17 08:06AM  See what the IHS Markit Score report has to say about Seattle Genetics Inc. Markit
Aug-12-17 08:07AM  See what the IHS Markit Score report has to say about Seattle Genetics Inc. Markit
Aug-11-17 07:31PM  Edited Transcript of SGEN earnings conference call or presentation 27-Jul-17 8:30pm GMT Thomson Reuters StreetEvents
Aug-10-17 08:07AM  IHS Markit Score upgrades Seattle Genetics Inc to 75 out of 100, despite ranking positively in only one IHS Markit category. Markit -5.17%
Aug-09-17 08:05AM  See what the IHS Markit Score report has to say about Seattle Genetics Inc. Markit
Aug-04-17 07:40AM  Corporate News Blog - Paul Sekhri Appointed Chairman of Board at Drug Discovery Company Compugen ACCESSWIRE
Aug-03-17 07:10AM  Corporate News Blog - Vertex Pharma Announces Approval from the FDA For KALYDECO in More Than 600 Patients Suffering from Cystic Fibrosis ACCESSWIRE
Aug-01-17 04:00PM  Seattle Genetics Announces Purchase of Bothell Manufacturing Facility from Bristol-Myers Squibb Business Wire
Jul-31-17 04:00PM  Seattle Genetics, Inc.: Expanded Sales on Their Way (FDA Willing) Motley Fool
03:19PM  ImmunoGen, Inc. Earnings: What Goes Up, Must Come Down Motley Fool
Jul-28-17 11:16AM  Seattle Genetics (SGEN) Q2 Loss Narrower than Expected Zacks
Jul-27-17 05:58PM  Seattle Genetics reports 2Q loss Associated Press
04:02PM  Seattle Genetics Reports Second Quarter 2017 Financial Results Business Wire
10:45AM  Investor Network: Seattle Genetics, Inc. to Host Earnings Call ACCESSWIRE
Jul-25-17 08:00AM  Health Canada Approves ADCETRIS® (Brentuximab Vedotin) for the Post-ASCT Consolidation Treatment of Patients with Hodgkin Lymphoma at Increased Risk of Relapse or Progression Business Wire
Jul-24-17 08:00AM  Seattle Genetics Announces Clinical Collaboration to Expand the Therapeutic Evaluation of SGN-LIV1A in Triple Negative Breast Cancer Business Wire
Jul-14-17 09:30AM  The Zacks Analyst Blog Highlights: Merck, Celgene, Gilead Sciences, Seattle Genetics and Vanda Pharmaceuticals Zacks
Jul-13-17 02:31PM  5 Drug Stocks Well Poised to Beat Q2 Earnings Estimates Zacks
Jul-06-17 08:00AM  Seattle Genetics to Host Conference Call and Webcast Discussion of Second Quarter Financial Results on July 27, 2017 Business Wire
Jul-04-17 10:37AM  What Analysts Recommend for United Therapeutics in June 2017 Market Realist
Seattle Genetics, Inc., a biotechnology company, develops and commercializes targeted therapies to treat cancer worldwide. It markets ADCETRIS, an antibody-drug conjugate for relapsed Hodgkin lymphoma and relapsed systemic anaplastic large cell lymphoma. The company also develops SGN-CD33A that is in Phase III clinical trial to evaluate SGN-CD33A in combination with hypomethylating agents in previously untreated older patients, as well as in Phase 1/2 clinical trial for patients with relapsed or refractory acute myeloid leukemia (AML); ASG-22ME, which is in Phase I clinical trial for Nectin-4-positive solid tumors, including bladder cancer; SGN-LIV1A that is in Phase 1 clinical trial for patients with LIV-1-positive metastatic breast cancer; and SGN-CD19A, which is in Phase II clinical trial for patients with relapsed DLBCL, as well as in Phase II trial for patients with newly diagnosed DLBCL. In addition, it is involved in developing SEA-CD40 that is in Phase I clinical trial for patients with solid tumors and hematologic malignancies; SGN-CD19B, which is in Phase I clinical trial ongoing for patients with relapsed or refractory aggressive B-cell non-Hodgkin lymphoma; SGN-CD123A that is in Phase I trial for patients with relapsed or refractory AML; SGN-CD352A, which is in Phase I clinical trial for patients with relapsed or refractory multiple myeloma; SGN-2FF that is in Phase I clinical trial for patients with advanced solid tumors; and ASG-15ME that is in Phase I clinical trial for patients with urothelial cancer. The company has collaborations for its ADC technology with various biotechnology and pharmaceutical companies, including AbbVie Biotechnology Ltd.; Bayer Pharma AG; Celldex Therapeutics, Inc.; Genentech, Inc.; GlaxoSmithKline LLC; Pfizer, Inc.; and Unum Therapeutics, Inc., as well as has co-development agreement with Agensys, Inc. and Genmab A/S. Seattle Genetics, Inc. was founded in 1998 and is headquartered in Bothell, Washington.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
DOBMEIER ERICChief Operating OfficerDec 04Option Exercise32.006,165197,300121,153Dec 06 08:04 PM
DOBMEIER ERICChief Operating OfficerDec 04Sale58.753,729219,092117,424Dec 06 08:04 PM
HIMES VAUGHN BChief Technical OfficerNov 30Option Exercise12.1610,000121,573172,306Dec 04 07:54 PM
HIMES VAUGHN BChief Technical OfficerNov 30Sale59.9710,000599,729164,906Dec 04 07:54 PM
DOBMEIER ERICChief Operating OfficerNov 17Option Exercise26.1010,000261,000127,424Nov 17 08:45 PM
DOBMEIER ERICChief Operating OfficerNov 17Sale59.1310,000591,250117,424Nov 17 08:45 PM
DOBMEIER ERICChief Operating OfficerNov 16Option Exercise20.2315,400311,617125,913Nov 17 08:45 PM
DOBMEIER ERICChief Operating OfficerNov 16Sale57.9615,400892,637117,424Nov 17 08:45 PM
DOBMEIER ERICChief Operating OfficerNov 15Option Exercise15.469,600148,416127,024Nov 17 08:45 PM
DOBMEIER ERICChief Operating OfficerNov 15Sale57.809,600554,837117,424Nov 17 08:45 PM
LIPPMAN MARC EDirectorNov 15Sale58.073,000174,224132,050Nov 17 08:47 PM
SIEGALL CLAY BPresident and CEONov 10Option Exercise11.0918,832208,847704,255Nov 14 07:40 PM
SIEGALL CLAY BPresident and CEONov 10Sale58.0018,8321,092,193687,146Nov 14 07:40 PM
SIMPSON TODD EChief Financial OfficerNov 01Sale60.9139,3852,398,915178,992Nov 03 05:42 PM
SIEGALL CLAY BPresident and CEOOct 11Option Exercise11.0918,832208,847694,045Oct 13 08:58 PM
SIEGALL CLAY BPresident and CEOOct 11Sale61.1818,8321,152,234687,146Oct 13 08:58 PM
DRACHMAN JONATHAN GCMO & EVP, R & DOct 05Option Exercise11.5217,816205,253151,518Oct 10 06:42 PM
SIEGALL CLAY BPresident and CEOSep 26Option Exercise11.099,01799,999687,146Sep 28 06:15 PM
SIEGALL CLAY BPresident and CEOSep 11Option Exercise11.0918,832208,847695,246Sep 12 07:34 PM
SIEGALL CLAY BPresident and CEOSep 11Sale53.4918,8321,007,257678,129Sep 12 07:34 PM
HIMES VAUGHN BChief Technical OfficerSep 08Option Exercise11.2310,000112,329171,742Sep 12 07:32 PM
HIMES VAUGHN BChief Technical OfficerSep 08Sale53.2210,000532,190164,906Sep 12 07:32 PM
Cline Darren SEVP, CommercialSep 06Option Exercise15.9410,048160,11582,254Sep 08 07:32 PM
SIMPSON TODD EChief Financial OfficerSep 06Sale52.009,638501,176218,377Sep 08 07:34 PM
Cline Darren SEVP, CommercialSep 06Sale51.945,024260,96777,230Sep 08 07:32 PM
Cline Darren SEVP, CommercialAug 31Option Exercise18.462,90753,66379,775Sep 05 07:23 PM
DOBMEIER ERICChief Operating OfficerAug 31Option Exercise15.4625,000386,500142,424Sep 05 07:25 PM
DOBMEIER ERICChief Operating OfficerAug 31Sale52.2425,0001,305,893117,424Sep 05 07:25 PM
Cline Darren SEVP, CommercialAug 31Sale52.517,569397,46672,206Sep 05 07:23 PM
SIMPSON TODD EChief Financial OfficerAug 28Sale47.894,937236,455228,015Aug 30 07:27 PM
SIEGALL CLAY BPresident and CEOAug 28Sale47.8925,5061,221,597678,129Aug 30 07:25 PM
HIMES VAUGHN BChief Technical OfficerAug 28Sale47.896,377305,423164,906Aug 30 07:24 PM
DRACHMAN JONATHAN GCMO & EVP, R & DAug 28Sale47.898,502407,199133,702Aug 30 07:23 PM
DOBMEIER ERICChief Operating OfficerAug 28Sale47.895,343255,900117,424Aug 30 07:21 PM
Cline Darren SEVP, CommercialAug 28Sale47.891,78885,63576,868Aug 30 07:18 PM
DRACHMAN JONATHAN GCMO & EVP, R & DAug 24Option Exercise10.2910,000102,900152,204Aug 25 07:52 PM
DRACHMAN JONATHAN GCMO & EVP, R & DAug 24Sale47.5410,000475,414142,204Aug 25 07:52 PM
Cline Darren SEVP, CommercialAug 07Option Exercise18.466,000110,76067,656Aug 09 06:52 PM
SIEGALL CLAY BPresident and CEOAug 07Option Exercise10.2910,413107,150646,848Aug 09 06:58 PM
SIEGALL CLAY BPresident and CEOAug 07Sale48.9110,413509,300636,435Aug 09 06:58 PM
Cline Darren SEVP, CommercialAug 07Sale49.196,000295,11061,656Aug 09 06:52 PM
DRACHMAN JONATHAN GCMO & EVP, R & DJul 27Option Exercise10.2910,000102,900125,204Jul 31 07:15 PM
DRACHMAN JONATHAN GCMO & EVP, R & DJul 27Sale54.5410,000545,361115,204Jul 31 07:15 PM
SIEGALL CLAY BPresident and CEOJul 05Option Exercise10.2910,423107,253644,629Jul 07 07:20 PM
SIEGALL CLAY BPresident and CEOJul 05Sale51.9810,423541,807636,435Jul 07 07:20 PM
DRACHMAN JONATHAN GCMO & EVP, R & DJun 22Option Exercise10.2910,000102,900125,204Jun 26 06:25 PM
DRACHMAN JONATHAN GCMO & EVP, R & DJun 22Sale64.0110,000640,058115,204Jun 26 06:25 PM
SIEGALL CLAY BPresident and CEOJun 05Option Exercise10.2910,423107,253646,195Jun 07 07:24 PM
SIEGALL CLAY BPresident and CEOJun 05Sale65.2110,423679,698636,435Jun 07 07:24 PM
HIMES VAUGHN BChief Technical OfficerMay 31Option Exercise9.2310,00092,300160,683Jun 02 07:08 PM
HIMES VAUGHN BChief Technical OfficerMay 31Sale62.5910,000625,922151,283Jun 02 07:08 PM
BAKER BROS. ADVISORS LPDirectorMay 15Option Exercise10.2020,000204,00040,895,092May 17 05:26 PM
SIEGALL CLAY BPresident and CEOMay 05Option Exercise10.2614,462148,450645,765May 09 07:42 PM
SIEGALL CLAY BPresident and CEOMay 05Sale61.7414,462892,897636,435May 09 07:42 PM
SIEGALL CLAY BPresident and CEOApr 05Option Exercise10.2614,465148,481646,858Apr 06 08:10 PM
SIEGALL CLAY BPresident and CEOApr 05Sale62.9914,465911,111636,435Apr 06 08:10 PM
HIMES VAUGHN BChief Technical OfficerMar 31Option Exercise9.2310,00092,300161,283Apr 04 05:48 PM
HIMES VAUGHN BChief Technical OfficerMar 31Sale62.7510,000627,527151,283Apr 04 05:48 PM
SIEGALL CLAY BPresident and CEOMar 06Option Exercise10.2614,465148,481646,858Mar 08 07:22 PM
SIEGALL CLAY BPresident and CEOMar 06Sale68.0414,465984,259636,435Mar 08 07:22 PM
SIEGALL CLAY BPresident and CEOFeb 06Option Exercise10.2614,465148,481646,758Feb 08 05:29 PM
SIEGALL CLAY BPresident and CEOFeb 06Sale61.5414,465890,164636,435Feb 08 05:29 PM
DRACHMAN JONATHAN GCMO & EVP, R & DJan 25Option Exercise10.295,00051,450114,837Jan 26 07:41 PM
SIEGALL CLAY BPresident and CEOJan 06Option Exercise10.2614,465148,481646,888Jan 10 06:11 PM
SIEGALL CLAY BPresident and CEOJan 06Sale57.8914,465837,425638,835Jan 10 06:11 PM
Cline Darren SEVP, CommercialDec 16Option Exercise16.413,10050,87161,604Dec 20 07:48 PM
Cline Darren SEVP, CommercialDec 13Option Exercise24.4512,761311,96865,743Dec 15 07:26 PM
Cline Darren SEVP, CommercialDec 13Sale63.3810,000633,83456,937Dec 15 07:26 PM
HIMES VAUGHN BChief Technical OfficerDec 12Option Exercise16.8915,632263,980151,011Dec 14 05:35 PM